MABp1 targeting interleukin-1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open-label extension period

Theodora Kanni, Maria Argyropoulou, Charles A Dinarello, John Simard, Evangelos J. Giamarellos-Bourboulis

Clinical and Experimental Dermatology 2021 Jan;46(1):162-163
DOI: 10.1111/ced.14333

View article 🡇

Funding

XBiotech, Texas
Hellenic Sepsis Study Group

Keywords: Hidradenitis Suppurativa
Related Study: HIDRA04

2023-02-16T14:28:16+03:00By hiss|Categories: Publications|Tags: Hidradenitis suppurativa|

Related Posts

Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial

Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial

March 14th, 2024 | 0 Comments

qSOFA combined with suPAR for early risk detection and guidance of antibiotic treatment in the emergency department: a randomized controlled trial

qSOFA combined with suPAR for early risk detection and guidance of antibiotic treatment in the emergency department: a randomized controlled trial

February 7th, 2024 | 0 Comments

Developing a Tool for Differentiation Between Bacterial and Viral Respiratory Infections Using Myxovirus Resistance Protein A and C-Reactive Protein

Developing a Tool for Differentiation Between Bacterial and Viral Respiratory Infections Using Myxovirus Resistance Protein A and C-Reactive Protein

February 2nd, 2024 | 0 Comments

Association of Vitamin D with Severity and Outcome of COVID-19: Clinical and Experimental Evidence

Association of Vitamin D with Severity and Outcome of COVID-19: Clinical and Experimental Evidence

January 5th, 2024 | 0 Comments

Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial

Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial

January 4th, 2024 | 0 Comments

Impact of Single Nucleotide Polymorphisms of the Promoter of the TNF Gene on Adalimumab Treatment Responses in Hidradenitis Suppurativa

Impact of Single Nucleotide Polymorphisms of the Promoter of the TNF Gene on Adalimumab Treatment Responses in Hidradenitis Suppurativa

October 28th, 2023 | 0 Comments

We use necessary cookies to make our website work properly and to store your choices in relation to optional cookies.
I want to be informed about the Cookies Policy
OK